Page 42 - Development Expense News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BioMarin Announces First Quarter 2021 Financial Results and Corporate Updates - Full-year 2021 Financial Guidance Reaffirmed - Total Revenues Grew 9% in the First Quarter 2021 Compared to First Quarter 2020, Excluding Kuvan - Regulatory Actions in Europe for Vosoritide and Valoctocogene Roxaparvovec Tracking as Expected; BioMarin Anticipates CHMP Opinion in June for Vosoritide and June Re-submission of MAA for Valoctocogene Roxaparvovec - FDA Review of Vosoritide Proceeding; PDUFA Target Action Date Extended to November 20, 2021 to Provide Time for Review of Recently Submitted 2-year Phase 3 ...

Share this article Share this article ResearchAndMarkets.com's offering. The Global Retail Point of Sale Market size is expected to reach $33.8 billion by 2026, rising at a market growth of 14.1% CAGR during the forecast period. Point of Sale (POS) is a place where buyers can carry out the payment for any goods or service and can also pay. The POS terminals & systems are utilized in physical spaces to initiate card payments. Points of sale are the main center of attraction for the marketers as consumers can make decisions about purchasing high-margin products or services at these strategic pl...

Apr 6, 2021 at 6:20AM Follow @jimhalley Johnson & Johnson (NYSE:JNJ) is the very definition of a value stock: five consecutive years of annual revenue growth, an above-average dividend that has been raised for 58 consecutive years in a row, and a diversified product portfolio capable of weathering various lawsuits, pandemics, and whatever else gets thrown its way. Last week, it was reported that a batch of 15 million doses of the company's vaccine that was being made for Johnson & Johnson by Emergent BioSolutions (NYSE:EBS) had to be thrown out because a m...

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Libervant™ (diazepam) Buccal Film New Drug Application (NDA) resubmission expected end of second quarter 2021 Epinephrine program and development strategy to be highlighted at a virtual investor event to be held at 9:00 a.m. ET on March 25, 2021 Entered U.S. licensing and supply agreement for Riluzole Oral Film for treatment of ALS with Mitsubishi Tanabe Pharma America Sympazan ® (clobazam) continues to meet key performance metrics Management to host conference call and webcast a...

- Full-year 2020 Total Revenues Increased 9% to $1.86 billion - Company Dose-escalates in PHEarless, a Phase 1/2 Study with BMN 307 Gene Therapy for the Treatment of Phenylketonuria (PKU); the Third Potential Therapeutic Modality in its PKU Franchise - During the Fourth Quarter, BioMarin Announced Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study - Marketing Applications for Vosoritide to Treat Children with Achondroplasia under Review in Europe and the U.S.; Committee for Medicinal Products for Human Use (CHMP) Opinion Ex...